Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 331

The DOI matches its Crossref record; 19 of the 19 references it cites were found in a registry or an index.

Nusinersen in adults with 5q spinal muscular atrophy: a non-interventional, multicentre, observational cohort study

Open access
Hagenacker, Tim, Wurster, Claudia D, Günther, René, Schreiber-Katz, Olivia, Osmanovic, Alma, Petri, Susanne, Weiler, Markus, Ziegler, Andreas, Kuttler, Josua, Koch, Jan C, Schneider, Ilka, Wunderlich, Gilbert, Schloss, Natalie, Lehmann, Helmar C, Cordts, Isabell, Deschauer, Marcus, Lingor, Paul, Kamm, Christoph, Stolte, Benjamin, Pietruck, Lena, Totzeck, Andreas, Kizina, Kathrin, Mönninghoff, Christoph, von Velsen, Otgonzul, Ose, Claudia, Reichmann, Heinz, Forsting, Michael, Pechmann, Astrid, Kirschner, Janbernd, Ludolph, Albert C, Hermann, Andreas, Kleinschnitz, Christoph · 2020 · The Lancet Neurology

Abstract

BACKGROUND Nusinersen is approved for the treatment of 5q spinal muscular atrophy of all types and stages in patients of all ages. Although clinical trials have shown improvements in motor function in infants and children treated with the drug, data for adults are scarce. We aimed to assess the safety and efficacy of nusinersen in adults with 5q spinal muscular atrophy. METHODS We did an observational cohort study at ten academic clinical sites in Germany. Patients with genetically confirmed 5q spinal muscular atrophy (age 16-65 years) with a homozygous deletion of exons 7, 8, or both, or with compound heterozygous mutations were eligible for inclusion and received nusinersen treatment in accordance with the label for a minimum treatment time of 6 months to a follow-up of up to 14 months. The primary outcome was the change in the total Hammersmith Functional Motor Scale Expanded (HFMSE) score, assessed at months 6, 10, and 14, and based on pre-post comparisons. This study is registered with the German Clinical Trials Register (number DRKS00015702). FINDINGS Between July 13, 2017, and May 1, 2019, 173 patients were screened, of whom 139 (80%) were eligible for data analysis. Of these, 124 (89%) were included in the 6-month analysis, 92 (66%) in the 10-month analysis, and 57 (41%) in the 14-month analysis; patients with missing baseline HFMSE scores were excluded from these analyses. Mean HFMSE scores were significantly increased compared with baseline at 6 months (mean difference 1·73 [95% CI 1·05-2·41], p<0·0001), 10 months (2·58 [1·76-3·39], p<0·0001), and 14 months (3·12 [2·06-4·19], p<0·0001). Clinically meaningful improvements (≥3 points increase) in HFMSE scores were seen in 35 (28%) of 124 patients at 6 months, 33 (35%) of 92 at 10 months, and 23 (40%) of 57 at 14 months. To 14-month follow-up, the most frequent adverse effects among 173 patients were headache (61 [35%] patients), back pain (38 [22%]), and nausea (19 [11%]). No serious adverse events were reported. INTERPRETATION Despite the limitations of the observational study design and a slow functional decline throughout the natural disease course, our data provide evidence for the safety and efficacy of nusinersen in the treatment of adults with 5q spinal muscular atrophy, with clinically meaningful improvements in motor function in a real-world cohort. FUNDING None.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/s1474-4422(20)30037-5

Cites

19 of 19 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 19 references

Cited by

See all 331

Metadata

Authors
Hagenacker, T., Wurster, C. D., Günther, R., Schreiber-Katz, O., Osmanovic, A., Petri, S., Weiler, M., Ziegler, A., Kuttler, J., Koch, J. C., Schneider, I., Wunderlich, G., Schloss, N., Lehmann, H. C., Cordts, I., Deschauer, M., Lingor, P., Kamm, C., Stolte, B., Pietruck, L., Totzeck, A., Kizina, K., Mönninghoff, C., von Velsen, O., Ose, C., Reichmann, H., Forsting, M., Pechmann, A., Kirschner, J., Ludolph, A. C., Hermann, A., & Kleinschnitz, C.
Venue
The Lancet Neurology
Publisher
Elsevier BV
Published
2020-04
Volume
19
Issue
4
Pages
317-325
ISSN
1474-4422 (ISSN-L)
OpenAlex
W3011851030
Cited by
331
References
19
FWCI
21.42
Type
journal article
Language
en
Open access
green

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Nusinersen in adults with 5q spinal muscular atrophy: a non-interventional, multicentre, observational cohort study. https://app.cochat.ai/papers/10.1016/s1474-4422(20)30037-5
The paper
Hagenacker, T., Wurster, C. D., Günther, R., Schreiber-Katz, O., Osmanovic, A., Petri, S., Weiler, M., Ziegler, A., Kuttler, J., Koch, J. C., Schneider, I., Wunderlich, G., Schloss, N., Lehmann, H. C., Cordts, I., Deschauer, M., Lingor, P., Kamm, C., Stolte, B., . . . Kleinschnitz, C. (2020). Nusinersen in adults with 5q spinal muscular atrophy: a non-interventional, multicentre, observational cohort study. The Lancet Neurology. https://doi.org/10.1016/s1474-4422(20)30037-5

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.